CV2: COST-EFFECTIVENESS OF TREATING HIGH-RISK INDIVIDUALS, AGED 45-65, WITH STATINS IN GERMANY FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART DISEASE  by Lauterbach, KW et al.
12 Abstracts
ID2
CIPROFLOXACIN IS MORE SUCCESSFUL AND 
COST-EFFECTIVE THAN TRIMETHOPRIM/
SULFAMETHOXAZOLE IN THE ORAL 
AMBULATORY TREATMENT OF WOMEN WITH 
UNCOMPLICATED ACUTE PYELONEPHRITIS
LeLorier J, Benhaddad A, LeLorier Y, Castilloux A-M, 
Desgagné A
Centre de recherche, Centre hospitalier de l’Université de 
Montréal, Campus Hôtel-Dieu, Québec, Canada
BACKGROUND: To compare the success rate and cost-
effectiveness (from the perspective of the healthcare pro-
vider) of ciprofloxacin (C) and trimethoprim/sulfamethox-
azole (TMP/SMX) in the ambulatory treatment of women
with acute uncomplicated pyelonephritis (AUPN). 
METHODS: A randomized double-blind study was per-
formed on women presenting to the emergency room
with symptoms of AUPN. Treatment regimens consisted
of either: C (500 mg) twice daily or TMP/SMX (160 mg/
800 mg) twice daily. Duration of treatment was 14 days.
The data necessary to calculate success rates and direct
medical costs were collected.
RESULTS: A total of 89 patients were randomized and in-
cluded in the cost-effectiveness analysis. Thirty-six patients
(C:19; TMP/SMX:17) were excluded from the success rate
analysis for the following reasons: 2 due to renal abnor-
malities (C:11; TMP/SMX:1), 3 due to failed urine cultures
(C:12; TMP/SMX:1), 9 due to resistance to TMP/SMX
(C:5; TMP/SMX:4), 16 due to negative urine cultures (C:7;
TMP/SMX:9), and 6 due to loss to follow-up (C:4; TMP/
SMX:2). Fifty-three evaluable patients remained (C:26;
TMP/SMX:27). Treatment success was defined as a negative
urine culture and absence of symptoms at the time of the fol-
low-up visit. Overall success rate: C: 22 of 26; TMP/SMX:
16 of 27 (p  0.0405). Direct medical costs: C: $278.39;
TMP/SMX: $546.15 Canadian (p  0.0048).
CONCLUSION: Ciprofloxacin produces fewer side effects
and has a higher cure rate than trimethoprim/sulfamethox-
azole. As a result, and despite its higher acquisition cost,
ciprofloxacin is more cost-effective than trimethoprim/sul-
famethoxazole in the ambulatory treatment of AUPN in
women.
ECONOMIC AND OUTCOMES STUDY RESULTS 
FOR CARDIOVASCULAR DISEASE
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PRELIMINARY QUALITY-OF-LIFE EVALUATION 
OF THE GERMAN SAT TRIAL: COMPARISON OF 
SF-36, EUROQOL, TIME TRADE-OFF METHOD, 
AND WILLINGNESS TO PAY METHOD
Kurscheid T, Hunsche E, Wendland G, Lauterbach KW
Institute for Health Economics at the University of Cologne, 
Cologne, Germany
OBJECTIVE: To assess the effectiveness of an evidence-
based treatment of obesity in a primary care setting, we
conducted the SAT trial (Sibutramine in Adiposity Trial),
a multicenter, double-blind, placebo-controlled, random-
ized parallel group comparison of a 54 weeks continuous
therapy with Sibutramine 15 mg or placebo, in addition
to a standardized nonpharmacological therapy consisting
of a calorie-restricted diet, modification of eating behav-
ior and lifestyle, and an activity program. Patients with a
body mass index (BMI) of greater than 30 and less than
40 were included. The primary endpoint in this study is
weight loss in kilograms between the last measurement of
body weight (visit 11) and the measurement at the first
visit. Secondary endpoints are, amongst other clinical pa-
rameters, health economic and quality of life data.
METHODS: Quality of life is measured by four different
instruments: the Short Form 36 (SF-36), the EuroQol, the
time trade-off method (TTO), and the willingness to pay
method (WTP). The SF-36 is a general, standardized and
validated quality-of-life instrument, consisting of 36 ques-
tions that can be aggregated into eight health dimensions.
The EuroQol is also a general, standardized and vali-
dated quality-of-life questionnaire, having the advantage
of aggregating the five health dimensions into one quality-
of-life index. Therefore, the EuroQol is frequently used in
health economic evaluations to calculate quality-adjusted
life-years saved (QALYs). In the TTO interview, patients
are asked questions so that we may calculate a quality-of-
life index for each patient (stratified by age). In the will-
ingness to pay questionnaire, obese patients are asked
how much they would be prepared to pay per month for
an immediate and sustained weight loss of 10 kg from
their current body weight. The answers are stratified by
net income classes.
RESULTS: Quality of life measured by the SF-36 has im-
proved in all eight health dimensions at visit 2 compared
to visit 1. Social functioning is especially impaired in
obese patients. The quality-of-life index measured by the
EuroQol has slightly improved from visit 1 to visit 2 over
all age groups. The results of the quality-of-life index of
the TTO interview and the EuroQol questionnaire are
very similar except in the age group 35 years. Willing-
ness to pay correlates positively with net income.
DISCUSSION: The results reveal the massive burden of
obese patients.
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COST-EFFECTIVENESS OF TREATING HIGH-
RISK INDIVIDUALS, AGED 45–65, WITH STATINS 
IN GERMANY FOR PRIMARY AND SECONDARY 
PREVENTION OF CORONARY HEART DISEASE
Lauterbach KW, Hunsche E, Klewer U
Institute for Health Economics and Clinical Epidemiology, 
University of Cologne, Cologne, Germany
Cost-effectiveness of primary and secondary prevention
of coronary heart disease in Germany was analyzed re-
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garding the potential effects of treating all patients with
hypercholesteremia age 45 to 65.
METHODS: The current analysis is based on a model
that approximates the discounted lifetime costs of all
patients who presented themselves in 1996 to a German
hospital for either primary or secondary events of coro-
nary heart disease. The costs of this cohort in 1996 and
up to their projected end of life were estimated, including
all direct and indirect costs. Data for direct costs were
generated from the federal bureau of statistics, sickness
funds, retirement funds, hospital admission data sources,
primary care panel physician data, and other sources. In
calculating indirect costs, gender- and age-specific unem-
ployment rates were considered. Additionally, the effects
on revenues and expenses for sickness funds and other
parts of the social security system were estimated. Thus,
the model allows cost-effectiveness studies from the per-
spective of society as well as from the perspective of the
social security system and parts of it, including the effects
on retirement payments.
RESULTS: Direct costs are approximately 31 billion US$
discounted at 4%. Indirect costs total 40 billion US$ dis-
counted at 4%. The model was used to calculate the cost-
effectiveness of treating all patients for secondary preven-
tion and all patients with a total cholesterol of 250 mg/dl
irrespective of further risk factors in the age group 45–65
from the perspective the social security system and the
perspective of society. For this age group, there is little
difference between these two perspectives and a com-
bined cost-effectiveness of 33,000 US$ per life-year saved.
The results are highly sensitive for the price of the pre-
scribed statins. 
CONCLUSION: Primary and secondary prevention can
be cost-effective in the age group 45–65 for both genders,
from both the perspective of society as well as the social
security system.
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UTILIZATION OF ACE INHIBITORS IN 
CONGESTIVE HEART FAILURE AMONG THE 
ELDERLY IN QUEBEC
LeLorier J, Couture J, Blais L, Castilloux A-M
Centre de recherche, Centre hospitalier de l’Université de 
Montréal, Campus Hôtel-Dieu, Québec, Canada
BACKGROUND: In 1991, SOLVD demonstrated a de-
crease in hospitalization and mortality rates by using an-
giotensin-converting enzyme inhibitors (ACEI) in chronic
congestive heart failure (CHF).
METHODS: We conducted a study on a 10% random
sample of subjects aged 65 years and older from the uni-
versal health insurance plan in Quebec. We studied all the
elderly who had a dispensation of digoxin (0.125 mg/d)
and furosemide (40 mg/d) (DF) from September 1991 to
December 1994.
RESULTS: Among 3,565 subjects, 61.7% used an ACEI at
least once after the first dispensation of DF. Visiting a car-
diologist was the strongest predictor of an ACEI dispensa-
tion (OR 1.58; 95% CI 1.44–1.74). The use of ACEI re-
mained stable from 1991 to 1994 (p  0.92). In a
subgroup of subjects free of ACEI and of any combination
of digoxin/furosemide 1 year prior to the first DF dispen-
sation (incident cases), 51.7% had at least one dispensa-
tion of an ACEI following the first dispensation of DF.
Among these incident users of DF, 79.3% began the ACEI
in the 3 months following the first dispensation of DF.
CONCLUSION: In the elderly taking digoxin and furo-
semide, the use of ACEI is widespread. Since the publica-
tion of SOLVD in 1991, there has been no change in the
utilization of ACEI over time.
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IMPROVED MYOCARDIAL PROTECTION 
DURING CORONARY BYPASS SURGERY 
SHORTENS HOSPITAL STAY AND SAVES COSTS
Mehlhorn U, Fattah M, Kuhn-Regnier F, Geissler HJ,
Südkamp M, Horst M, Hekmat K, Dapunt O, de Vivie ER
Clinic for Cardiothoracic Surgery, University of
Cologne, Germany
OBJECTIVES: We have recently shown that continuous
coronary perfusion with warm blood enriched with the
ultra–short acting -blocker Esmolol (ES) improves func-
tional and structural myocardial protection during coro-
nary artery bypass grafting (CABG) as compared with
conventional cardioplegia (CP). The purpose of the present
study was to compare the myocardial protection tech-
niques in terms of patient outcome and economical as-
pects.
METHODS: We retrospectively analyzed the charts of
150 consecutive patients who received CABG using the
ES technique; 150 patients matched for age, gender, pre-
operative left ventricular function, history of renal fail-
ure, and history of neurological symptoms who under-
went CABG using the conventional CP-technique served
as the control group.
RESULTS: There were no significant differences between
the groups with respect to perioperative myocardial in-
farction rate, need for positive inotropic medication, need
for mechanical circulatory support, duration of mechani-
cal ventilation, duration of intensive care unit stay, time
of mobilization, postoperative renal failure, cardiac ar-
rhythmias, neurological symptoms, infections or in-hospi-
tal mortality. However, ES patients were less frequently
re-admitted to the intensive care unit (ES: 3 of 150 [2%]
vs. CP: 13 of 150 [9%]; p  0.015) and discharged ear-
lier from the hospital (ES: 12.3  4.8 days vs. CP: 13.5 
3.8 days; p  0.009). In addition, the ES technique itself
was more economical (drug costs for ES technique: about
DM 120 per patient vs. CP technique: about DM 260 per
patient). 
CONCLUSIONS: Our data suggest that improved myo-
cardial protection during CABG using the ES technique
may be a cost-saving alternative to the conventional CP
technique due to both shorter hospital stay and lower
procedural costs.
